Lilly to Acquire 3 Vaccine Firms for Up to $4B, Reports Strong PCSK9 Drug Data
LLY sits 71% above its 52-week low of $623.78.
Summary
Eli Lilly announced it will acquire three vaccine companies for up to $4 billion, marking a strategic expansion into the vaccine market. Separately, the company reported highly positive Phase 1b results for a PCSK9 inhibitor, demonstrating up to an 88% reduction in PCSK9 and a 62% reduction in LDL-C. This promising drug candidate has FDA fast-track status, with Phase 2 trials expected to begin by year-end. These developments continue a strong period for Lilly, following recent FDA approvals and robust financial performance, and further diversify its pipeline beyond its successful GLP-1 franchise.
At the time of this announcement, LLY was trading at $1,069.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.